Inventor
JASON TIERNEY
Inventor
GB
Overview
Patents· 6 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations32%
C07DHeterocyclic compounds32%
C07BGeneral methods of organic chemistry21%
A61KPreparations for medical, dental or toiletry purposes16%
PatentTitleYear
12,552,807PCSK9 inhibitors and methods of use thereof202612,428,413Rho kinase inhibitors and compositions and methods of use thereof202512,152,038Vasopressin receptor antagonists and products and methods related thereto202411,858,943Vasopressin receptor antagonists and products and methods related thereto202411,248,001PCSK9 inhibitors and methods of use thereof202211,186,577Vasopressin receptor antagonists and products and methods related thereto2021Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2021Patents assigned to BLACKTHORN THERAPEUTICS INC (1)· patent assignee history
2021–2026Based in GB· patent location history
2022–2026Patents assigned to ASTRAZENECA AB (2)· patent assignee history
2024Patents assigned to NEUMORA THERAPEUTICS INC (2)· patent assignee history
2025Patents assigned to CHDI FOUNDATION INC (1)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| ASTRAZENECA AB | 2 | 2022–2026 |
| NEUMORA THERAPEUTICS INC | 2 | 2024 |
| BLACKTHORN THERAPEUTICS INC | 1 | 2021 |
| CHDI FOUNDATION INC | 1 | 2025 |
Locations
| Location | Patents | Span |
|---|---|---|
| GB | 6 | 2021–2026 |